A novel combination therapy drastically reduces the infection rate of three prevalent viruses -- and risk of death -- in transplant patients with compromised immune systems. Trivirus-specific cytotoxic T lymphocytes (CTLs), the first multivirus killer of its kind, called, controlled infections caused by three commonplace viruses -- cytomegalovirus (CMV), Epstein-Barr virus (EBV), and adenovirus -- with no toxicity in a phase 1 trial.
More...